SU301951A1 - Лекарственное средство - Google Patents

Лекарственное средство

Info

Publication number
SU301951A1
SU301951A1 SU1438661A SU1438661A SU301951A1 SU 301951 A1 SU301951 A1 SU 301951A1 SU 1438661 A SU1438661 A SU 1438661A SU 1438661 A SU1438661 A SU 1438661A SU 301951 A1 SU301951 A1 SU 301951A1
Authority
SU
USSR - Soviet Union
Prior art keywords
medicine
drug
acid
chronic
treatment
Prior art date
Application number
SU1438661A
Other languages
English (en)
Original Assignee
В. А. Чернов, Т. С. Сафонова, Н. В. Сазонов, А. А. Кропачева,
Д. Ключарева, Л. Г. Лыткина , Т. А. Ерофеева Всесоюзный научно исследовательский химико фармацевтический институт Серго Орджоникидзе
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by В. А. Чернов, Т. С. Сафонова, Н. В. Сазонов, А. А. Кропачева,, Д. Ключарева, Л. Г. Лыткина , Т. А. Ерофеева Всесоюзный научно исследовательский химико фармацевтический институт Серго Орджоникидзе filed Critical В. А. Чернов, Т. С. Сафонова, Н. В. Сазонов, А. А. Кропачева,
Priority to SU1438661A priority Critical patent/SU301951A1/ru
Priority to DE19712114597 priority patent/DE2114597A1/de
Priority to BE764991A priority patent/BE764991A/xx
Priority to FR7112516A priority patent/FR2093926B1/fr
Priority to GB2707171*#A priority patent/GB1316006A/en
Application granted granted Critical
Publication of SU301951A1 publication Critical patent/SU301951A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/224—Phosphorus triamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Description

(Изо|бретение относитс  к медицине, точнее к противоопухолевым лекарственным средствам .
(Предлагаетс  применение в медиЦИнокой практике, тари гемодерми х диэтиленимида 1пирИМИ|ДИЛ-2-аМИД01фосфорН1ОЙ кислоты (фосфе|МИда ).
ФОСфемид хорошо переноситс  больными и в отлИчие от производных етиленимина не вызывает т желого угнетени  кроветворени . Развивающа с  в отдельных случа х небольша  лейкопени  о1бычно носит време-нный характер . После назначени  нуклеинощокислого натри  или отмены препарата число лейкоцитов быстро восста навливаетс  до, нормы.
Фоафемид обладает также отчетливой противоопухолевой активностью в отношении
других злокаче-стзейных локализаций ( ичники , молочна  железа) и некоторых гемоблаCT03QB (лим1фо1грануло1матов, хронический Миелолей-коз, хронический лим|фолеЙ1Коз). Препарат реко1мендуетс  вводить виутримышечно по 5-10 мг (1-2 мл 0,5%-ino раствора ) 2-3 раза в неделю. При отсутствии достаточного терапевтического эффекта и при хорошей переносимости разовую дозу препарата можно довести до ,15-20 мг. На курс лечени  требуетс  120-200 мг фосфемцда (10-20 инъеюций).
Предмет изобретени 
При.менение диэтиленимида пиримидил-2амидофосфорно-й кислоты (1фОсфеМнда,) три лечении 1ге1МОдерми1Й.
SU1438661A 1970-06-01 1970-06-01 Лекарственное средство SU301951A1 (ru)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SU1438661A SU301951A1 (ru) 1970-06-01 1970-06-01 Лекарственное средство
DE19712114597 DE2114597A1 (de) 1970-06-01 1971-03-25 Zytostatisches Arzneipraparat
BE764991A BE764991A (fr) 1970-06-01 1971-03-30 Produit pharmaceutique antitumoral et son procede de preparation
FR7112516A FR2093926B1 (ru) 1970-06-01 1971-04-08
GB2707171*#A GB1316006A (en) 1970-06-01 1971-04-19 Pharmaceutically active chemical compound and an antitumourigenic preparation containing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU1438661A SU301951A1 (ru) 1970-06-01 1970-06-01 Лекарственное средство

Publications (1)

Publication Number Publication Date
SU301951A1 true SU301951A1 (ru) 1973-04-05

Family

ID=20452986

Family Applications (1)

Application Number Title Priority Date Filing Date
SU1438661A SU301951A1 (ru) 1970-06-01 1970-06-01 Лекарственное средство

Country Status (5)

Country Link
BE (1) BE764991A (ru)
DE (1) DE2114597A1 (ru)
FR (1) FR2093926B1 (ru)
GB (1) GB1316006A (ru)
SU (1) SU301951A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219866A (en) * 1991-07-04 1993-06-15 Asta Medica Ag Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphate and a process for its preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219866A (en) * 1991-07-04 1993-06-15 Asta Medica Ag Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphate and a process for its preparation

Also Published As

Publication number Publication date
FR2093926A1 (ru) 1972-02-04
FR2093926B1 (ru) 1975-06-06
BE764991A (fr) 1971-08-16
GB1316006A (en) 1973-05-09
DE2114597A1 (de) 1972-01-20

Similar Documents

Publication Publication Date Title
US5852057A (en) Anticarcinogenic drug composition
SU301951A1 (ru) Лекарственное средство
JPS5938203B2 (ja) 補酵素ｑを主成分とする脳循環障害治療剤
US3019167A (en) Method of administering streptokinase systemically
Barker et al. The effect of quinidine upon sinus tachycardia, including the production of transient bundle branch block
Quick et al. Vitamin K requirements of adult dogs and the influence of bile on its absorption from the intestine
Powell et al. A comparative trial of dehydroemetine and emetine hydrochloride in identical dosage in amoebic liver abscess
GB950162A (en) Medicines for the treatment of hepatic disorders
SU552085A1 (ru) Средство дл лечени нарушений свертывающей системы крови при тромбоцитопенических состо ни х различного происхождени и дл стимул ции гемоопоэза "эритрофосфатид"
HC et al. INTRMUSCULAR INJECTION OF PROCAINE PENICILLIN COMBINED WITH ORAL ADMINISTRATION OF AMPICILLIN IN THE TREATMENT OF GONORRHOEA.
GB1246315A (en) Pharmaceutical compositions
US4062974A (en) Method for treating drepanocytosis
SU429813A1 (ru) Способ лечения туберкулеза легких
Guyer Stokes-Adams attacks precipitated by hypokalaemia
SU263807A1 (ru) Новый способ лечени анемии и озены
Ota et al. A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia.
JPS6345371B2 (ru)
Eisenberg et al. The effect of ethylenediaminetetraacetic acid (EDTA) and ascorbic acid on tetracycline blood serum concentrations
WJ et al. Dequalinium in myasthenia gravis.
US3789124A (en) Treatment of colitis ulcerosa
Wils et al. Recurrence of hyperthyroidism shortly after return of normal suppressibility by triiodothyronine.
SU1393401A1 (ru) Способ лечени абсцесса легкого
GB1327469A (en) Pharmaceutical compositions for inhibiting indoleamine n-methyl transferase
Sanazaro Acetyldigitoxin in therapy of ambulatory patients with congestive heart failure
SU374086A1 (ru) ЛЕКАРСТВЕННОЕ СРЕДСТВО''^ --''ОсНАЯ'•'^^^bju;r---jc^'-;^..':. :0 •--.:А |:'*''~'"~~ •' - ——«-.«aSJ^iH.